NervGen Pharma (NASDAQ:NGEN) Issues Quarterly Earnings Results

NervGen Pharma (NASDAQ:NGEN) issued its quarterly earnings results on Thursday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.28), Zacks reports.

NervGen Pharma Price Performance

Shares of NGEN stock remained flat at $1.76 during mid-day trading on Thursday. The stock had a trading volume of 553,002 shares, compared to its average volume of 494,818. The business has a fifty day simple moving average of $1.85. NervGen Pharma has a 12-month low of $1.58 and a 12-month high of $6.30. The firm has a market cap of $141.91 million and a PE ratio of -19.56.

Wall Street Analyst Weigh In

NGEN has been the topic of several research analyst reports. Zacks Research raised NervGen Pharma to a “hold” rating in a research note on Wednesday, April 29th. Stifel Nicolaus raised NervGen Pharma to a “strong-buy” rating in a research note on Thursday, April 23rd. Weiss Ratings cut shares of NervGen Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 4th. TD Cowen started coverage on shares of NervGen Pharma in a research report on Thursday, June 11th. They set a “buy” rating for the company. Finally, HC Wainwright raised shares of NervGen Pharma to a “strong-buy” rating in a research note on Tuesday, April 28th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.